



(11)

**EP 2 683 242 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 31/407** <sup>(2006.01)</sup> **A61P 25/28** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2012/026984**

(48) Corrigendum issued on:  
**03.06.2020 Bulletin 2020/23**

(87) International publication number:  
**WO 2012/154285 (15.11.2012 Gazette 2012/46)**

(45) Date of publication and mention  
of the grant of the patent:  
**08.04.2020 Bulletin 2020/15**

(21) Application number: **12782326.8**

(22) Date of filing: **28.02.2012**

(54) **EFFECTIVE AMOUNTS OF  
(3AR)-1,3A,8-TRIMETHYL-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL  
PHENYLCARBAMATE AND METHODS THEREOF**

WIRKSAME MENGEN VON  
(3AR)-1,3A,8-TRIMETHYL-1,2,3,3A,8,8A-HEXAHYDROPYRROLO-[2,3-B]-INDOL-5-YL-PHENYLC  
ARBAMAT UND VERFAHREN DAFÜR

QUANTITÉS EFFICACES DE  
(3AR)-1,3A,8-TRIMÉTHYL-1,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL  
PHÉNYLCARBAMATE ET LEURS PROCÉDÉS

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**  
Designated Extension States:  
**BA ME**

(74) Representative: **Dehns**  
**St. Bride's House**  
**10 Salisbury Square**  
**London EC4Y 8JD (GB)**

(30) Priority: **04.03.2011 US 201113041211**

(56) References cited:  
**WO-A1-2005/089746 WO-A2-2010/117727**  
**US-A1- 2002 094 999 US-A1- 2005 013 869**

(43) Date of publication of application:  
**15.01.2014 Bulletin 2014/03**

(73) Proprietor: **Annovis Bio, Inc.**  
**Berwyn, PA 19312 (US)**

- **HAROLD W HOLLOWAY ET AL: "Posiphen and  
Analogues: Experimental Alzheimer Agents that  
Reduce Amyloid-[beta] Peptide by Lowering  
Amyloid Precursor Protein Levels in Culture and  
In Vivo", 42ND ANNUAL WINTER CONFERENCE  
ON BRAIN RESEARCH, 25 January 2009  
(2009-01-25), XP055130785, 42nd Annual Winter  
Conference on Brain Research**

(72) Inventor: **MACCECCHINI, Maria**  
**West Chester, PA 19380 (US)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 683 242 B8**

- Maria L Maccacchini ET AL: "Posiphen: Experimental Alzheimer Agent that Lowers Amyloid Precursor Protein Levels in Culture and In Vivo", , 12 July 2009 (2009-07-12), XP055130786, International Conference on Alzheimer's Disease Retrieved from the Internet: URL: [http://www.qrpharma.com/pdf/ICAD\\_Posiphen\\_06-30-2009.pdf](http://www.qrpharma.com/pdf/ICAD_Posiphen_06-30-2009.pdf) [retrieved on 2014-07-22]
- Maria Maccacchini ET AL: "Targeting Alzheimer's with Novel Therapeutics", , 11 May 2010 (2010-05-11), XP055130807, Neuroscience Network Retrieved from the Internet: URL: [http://www.qrpharma.com/pdf/2010-5-11AlzheimersResearchTodayMariaMaccacchini\\_slides.pdf](http://www.qrpharma.com/pdf/2010-5-11AlzheimersResearchTodayMariaMaccacchini_slides.pdf) [retrieved on 2014-07-22]
- Maria L. Maccacchini: "Mechanism of Action of Posiphen : From Model to Human", , 26 January 2011 (2011-01-26), XP055130818, 44nd Annual Winter Conference on Brain Research Retrieved from the Internet: URL: [http://www.qrpharma.com/pdf/WCBR\\_Talk\\_Jan\\_2011.pdf](http://www.qrpharma.com/pdf/WCBR_Talk_Jan_2011.pdf) [retrieved on 2014-07-22]
- KADIR A ET AL: "Long-term effect of phenserine treatment in Alzheimer patients as assessed by PET and CSF biomarkers", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 5, no. 4, 1 July 2009 (2009-07-01), page P6, XP026897327, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2009.05.019 [retrieved on 2009-07-01]
- MACCECCHINI ET AL.: 'Posiphen lowers amyloid precursor protein and amyloid beta as well as acetylcholinesterase levels in culture, animals and humans' INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE vol. 5, no. 4, 12 July 2009, XP026253808 Retrieved from the Internet: <URL: [http://www.qrpharma.com/pdf/ICAD\\_Posiphen\\_06-30-2009.pdf](http://www.qrpharma.com/pdf/ICAD_Posiphen_06-30-2009.pdf)> [retrieved on 2012-05-19]
- U.S. Department Of Health And Human Services Food And Drug Administration Center For Drug Evaluation And Research (cder): "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", , 6 July 2005 (2005-07-06), XP055568568, Retrieved from the Internet: URL: <https://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf#search='guide+kines+for+industry+sfe+starting'> [retrieved on 2019-03-13]
- Jack T. Rogers ET AL: "The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen", Journal of Neural Transmission, vol. 118, no. 3, 8 January 2011 (2011-01-08), pages 493-507, XP055625613, Vienna ISSN: 0300-9564, DOI: 10.1007/s00702-010-0513-5
- D.K. Lahiri ET AL: "The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice", Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, 27 June 2006 (2006-06-27) , pages 386-396, XP055130741, ISSN: 0022-3565, DOI: 10.1124/jpet.106.112102

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification